"After a strong second quarter, the third quarter of 2022 continued with good sales growth in most of the company's markets. The development is in line with our long-term ambitions to create sustainable sales growth."
July -
Net sales:
Operating income:
Net income for the period:
Earnings per share:
Events in the third quarter
- Continued post COVID-19-market rebound with an increased order intake from most of the company ́s markets.
-
First order for Glycosorb® ABO from distributor in
Chile . -
New transplant centers added in
India -
Participation as an exhibitor at the STS (
Scandinavian Transplant Society ) inReykjavik and at the TTS (The Transplantation Society ) inBuenos Aires -
Glycosorb® ABO was used at the largest heart transplant center in
Germany to enable a blood group incompatible heart transplant on a two- year-old girl. The treatment with Glycosorb® ABO went excellent and the child was successfully transplanted. - Meetings with potential key customers for the UBP-product in key European markets.
- Excellent results presented at the DGTI in Mannheim.
-
In September, the Board of Directors appointed Johan Lavén as the new CEO of the company after
Geert Nygaard resigned in July.
Significant events after the balance sheet date
Oct 27, 2022 : Excellent results from platelet evaluation inEngland
THE ENTIRE INTERIM REPORT FOR QUARTER 3 2022 IS ATTACHED
For further information, please contact:
Scheelevägen 27
SE-223 63
Phone: +46 46 286 5230
info@glycorex.com
glycorex.com
This information is such information that
Brief information about the company
Glycosorb® ABO is one of
The company has also developed a CE-marked medical device product for the production of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases. The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.
https://news.cision.com/glycorex-transplantation/r/glycorex-transplantation-ab--gtab-b--interim-report-january---september-2022,c3672017
https://mb.cision.com/Main/15286/3672017/1691956.pdf
(c) 2022 Cision. All rights reserved., source